Ashion® leverages advanced clinical genomic sequencing and analysis technology developed through research at The Translational Genomics Research Institute® (TGen®). Ashion’s number one priority is to deploy this technology commercially to help more patients. This technology was used in the world’s first clinical studies for personalized cancer treatment selection, and Ashion hopes to continue to partner with research collaborators for impactful clinical studies.

Research Partnerships

Ashion Analytics™ is proud to partner with TGen as its clinical sequencing provider for several important clinical studies, such as precision medicine trials for brain cancer and multiple myeloma patients, and a multicenter study to evaluate the feasibility of molecularly guided therapy in patients with relapsed or refractory childhood cancers. In these trials Ashion collaborates with dozens of academic and commercial partners across the world to deliver high quality and reliable clinical genomic results.